Find Funding Opportunities

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the SBC is expected to maintain oversight and management of the R and D throughout the award.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the SBC is expected to maintain oversight and management of the R and D throughout the award.

The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients.Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials.

This FOA seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the NIH is now expanding the program to include additional participating NIH and CDC Institutes and Centers. The expanded I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this funding opportunity announcement (FOA), participating NIH and CDC Institutes and Centers will provide administrative supplement awards to a cohort of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

The purpose of this, Inter-Agency Funding Opportunity Announcement (FOA) is to develop and validate the infrastructure for rapid and effective conduct of future research utilizing technology to facilitate aging in place, with a special emphasis on people from underrepresented groups.

This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The goal of this FOA is to provide informatics support to NIH funded projects that are performing high-throughput broad based phenotyping of mouse knock-out (KO) lines (see RFA-RM-15-017) and to coordinate with international efforts so as to integrate all data into a common database under the auspices of the International Mouse Phenotyping Consortium (IMPC). The Data Coordination Center and Database (DCCDB) will perform the curation, analysis, visualization, and dissemination of the phenotype data from the knockout lines. Curation will require integration with other data sources. Analysis will require further development and validation of statistical methods.Visualization and queries will require innovative tools to disseminate the data in a real-time environment. The ultimate goals of these efforts are to enhance the ability of the biomedical research community to identify new disease models, to better understand phenotypic patterns, and to gain a more comprehensive understanding of the underlying function of each gene.

This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. The purpose of this FOA is to solicit applications for research projects to make maximum progress toward the goal of producing a null-mutant mouse phenotype resource for each gene in mouse strain C57BL/6, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The specific objectives of this FOA are to generate mutant mouse lines using CRISPR/Cas9 technology, perform phenotyping assays, conduct quality control assessments, cryopreserve germplasm, and make mice and data readily available to the research community. The mouse is the ideal mammalian system in which to produce a functional genomics resource because of the long history and depth of understanding of mouse genetics, the sophistication of assistive reproductive technology in the mouse system, short generation times, and the low cost of working with mice in comparison to other mammals. The recent breakthroughs in CRISPR/Cas9 technology make the mouse an even more cost effective model system and will drive technology of mouse production. The goal of this FOA is to support high-throughput broad based phenotyping of approximately 600 null-mutant mouse lines per year, with an overall goal of 3,000 lines for this five-year project period of the Knockout Mouse Phenotyping Program (KOMP2).

Invasive surgical procedures provide the unique ability to record and stimulate neurons within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and are rarely aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this FOA seeks applications to assemble integrated, multi-disciplinary teams to overcome these fundamental barriers. Projects should investigate high-impact questions in human neuroscience and disorders of the human nervous system. The research should be offered as experimental projects, or exploratory research and planning activities, for building teams, generating data and empirical results that will later compete for continued funding under new or ongoing FOAs of the BRAIN Initiative or under NIH Institute appropriations.

This Funding Opportunity Announcement (FOA) invites Cooperative Agreement (U10) applications for implementation of investigator-initiated randomized controlled clinical trials on alcohols effects on neurological diseases, most especially stroke, and the health issues that are associated with aging. Applicants for the U10 Clinical Trial Implementation Cooperative Agreement must be able to begin the trial without further planning activities when the U10 is awarded. Therefore, investigators who have already completed planning activities through an NIAAA-funded U34 clinical trial planning grant are expected to apply.

This Funding Opportunity Announcement (FOA) invites applications for Center Core Grants that provide resources and facilities shared by a minimum of six NINDS-supported investigators, and supporting a wider base of neuroscience research. The proposed Centers should offer services and expertise that would be difficult or impractical to support in individual labs. The Centers are expected to capitalize on economies and synergies associated with shared resources, and to foster a collaborative environment among neuroscientists at host institutions.